TORONTO, Dec. 15, 2020 (World NEWSWIRE) — Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) is pleased to report financial results for the third quarter of fiscal 2021, the period ending Oct 31, 2020. All figures are described in U.S. bucks.
| Q3 ending October 31, 2020 | Q3 ending October 31, 2020 | |
| Product sales | 1,228,855 | 1,215,105 |
| Web Revenue | 23,607 | 73,782 |
| Profits for each prevalent share – basic | .01 | .02 |
| – diluted | .01 | .02 |
| Weighted avg. popular shares | ||
| Outstanding – standard | 3,432,478 | 3,419,478 |
| – diluted | 3,432,478 | 3,444.868 |
The firm fundamentals continue being solid with a great cash placement and stability sheet even in gentle of the COVID-19 pandemic.
The need for Native Dextran was constant all through the 3rd quarter, has fluctuated in Q4 as a result far, but seems to have stabilized going forward. The COVID pandemic continues to induce uncertainty with some clients, who are cautious about forecasting their demands with any clarity.
George Usher, President and CEO mentioned “We are delighted that we have been in a position to stay successful this calendar year, in spite of the worldwide effect of the Covid-19 pandemic.” He also observed that “Our purchaser base is largely engaged in the generation of close-use pharmaceutical factors both equally for veterinary and human use, and as these types of are crucial corporations to be taken care of, albeit with a bigger degree of protection protocols for workers.”
The Company’s publicly traded shares continue to be quoted on the OTC Pink Sheet system ( www.otcmarkets.com/stock/POLXF/estimate ).
The organization carries on complete disclosure of its fiscal and operational success, which can be accessed by browsing the organization web page at www.Polydex.com. Solution data is obtainable at www.dextran.ca
Polydex Prescribed drugs Minimal, primarily based in Toronto, Ontario, Canada, is engaged in the production of bulk pharmaceutical intermediates for the throughout the world veterinary pharmaceutical marketplace, and also the advancement, production and advertising of biotechnology-based mostly for items for the human pharmaceutical industry.
Business website: www.Polydex.com
Take note: This press launch could have ahead-wanting statements, within just the which means of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, pertaining to Polydex Prescribed drugs Limited, including, with out limitation, statements about expectations about future revenues or organization alternatives or opportunity research projects. These statements are generally discovered by use of text like “may”, “could”, “might”, “expect”, “anticipate”, “believe”, or related text. Genuine situations or success may well differ materially from the Company’s expectations, which are subject to a quantity of known and mysterious threats and uncertainties which include but not restricted to modifying market situations, foreseeable future actions by the United States Foodstuff and Drug Administration or equal international regulatory authorities. Other hazard components reviewed in the Company’s monetary studies may well also have an effect on the genuine final results obtained by the Firm.
Get hold of:
Investor Relations: Linda Hughes, [email protected]
More Stories
Sales Build in November as Inventories Grow
A Two-Way Communication Tool for Teachers
My 50th birthday celebrations in Amsterdam